Joseph McCorkle, Jr., of Balch & Bingham, Montgomery, and Ryburn H.
Graber, of Kirkland & Ellis, Chicago, Ill., for appellant.Ĭharles M. Clark, of Lange, Simpson, Robinson & Somerville, Birmingham, and James W. Hill II of Hill, Hill, Carter, Franco, Cole & Black, Montgomery, William G. "There are plenty of opportunities to work together and prove that clinical transformation works.”įor more information or to begin an application, visit vitalinnovationprogram.PROTECTIVE LIFE INSURANCE COMPANY, Alabama Association of Life Insurance Companies, and Health Insurance Association of America. We want to work with innovators who are trying to improve care while making it sustainable," Rodgers adds. “We’d love to hear from physicians who have an interest in solving any unmet clinical needs. This tool reduced the number of unnecessary invasive coronary angiograms by over 83 percent and saved an estimated $2,844 per patient. 1, 2018, Highmark will cover HeartFlow ®, a non-invasive diagnostic technology that offers physicians insight into both the extent of a patient's coronary arterial blockage and the impact the blockage has on blood flow. And, the treatment resulted in more than 50 percent greater savings than standard invasive surgical procedures.Īs of Jan. Participants reported a positive change in quality of life satisfaction from 8 to 92 percent. LINX is a circular bracelet of titanium magnets fitted around the base of the esophagus that keeps digestive acids from climbing out of the stomach. And that can give patients faster access to new promising treatments.*įor example, based on data gained from VITAL’s initiative with the LINX ® Reflux Management System for gastro-esophageal reflux disease (GERD), Highmark started to cover it in June 2017. VITAL collects the clinical and financial data to make a case for care management and reimbursement policies. When doctors or industry partners identify a potential new treatment, technology, or procedure, VITAL’s support helps them gain insights and collect the needed data to demonstrate the effectiveness of the innovation. “VITAL brings all of the pieces together - the innovation or procedure, with the clinician, with the patients - so we can gather the data needed to move the idea from investigational to fully reimbursable,” she explains. Recently, Provider News spoke with Eileen Rodgers, director of the program. By coordinating efforts among researchers, data scientists, clinicians, and patients, VITAL collapses traditional barriers to market adoption in an effort to:Īcting as a bridge between innovators and clinicians, VITAL also champions changes in coverage and reimbursement decisions. VITAL serves as a streamlined, test-and-learn engine for bringing new medical technologies, innovations, and services to market more quickly.
Effective deployment of new solutions could drive better care at a lower cost.
Highmark Health is poised to help drive innovation, discover new interventions, and improve the experience, access, outcomes, and affordability of health care. And, new FDA-approved medical technologies can take 15 months to five years before Medicare covers them. A new medical device can take three to seven years from concept to market. VITAL's overall goal is to make new technologies and services available sooner for patients.Īpproved, market-ready innovations often languish while insurers study and test them to decide on coverage decisions. In 2015, Highmark Health launched VITAL - a program that provides the missing link between FDA approval of a new medical technology and its reimbursement by commercial insurers.
0 kommentar(er)
